Financing and Investment Products

Corporate / M&A

Capital Markets

Santhera

On May 4, 2021, Santhera Pharmaceuticals Holding AG (SIX: SANN) announced the settlement of the first exchange offer for a convertible bond in Switzerland. Holders of Santhera&#8217;s existing CHF 60 m Senior Unsecured Convertible Bonds due 2022 received one new CHF 30,270,375 Senior Unsecured Convertible Bond due 2024 and 26 Santhera shares per existing bond. The offer had been accepted by holders of 74.7% of the former bonds.
Homburger acted as transaction counsel in this matter. The team was led by partners Dieter Gericke and Daniel Häusermann (both Corporate / M&amp;A, Capital Markets). Key members of the team included partner Stefan Oesterhelt (Tax), counsel Eduard De Zordi (Financing and Investment Products) and associates Marco Rostetter and Romain Fakhoury (both Corporate / M&amp;A, Capital Markets), as well as Pierina Janett-Seiler and Daniel Junginger (both Financing and Investment Products) and junior associate Daniel Bötticher.

Homburger advises Santhera on the First Exchange Offer for a Convertible Bond in Switzerland and Issuance of New Senior Unsecured Convertible Bonds due 2024

On April 29, 2021, PolyPeptide Group AG, a global leader in peptide development and manufacturing, announced the successful pricing of its initial public offering (IPO) at CHF 64 per share, implying a market capitalization of CHF 2.12 bn. The base offering of the IPO comprised 3,125,000 new shares issued in a capital increase and 8,396,740 existing shares sold by the selling shareholder, Draupnir Holding B.V. In addition, the selling shareholder has granted an over-allotment option to the underwriters of up to 1,728,261 existing shares, exercisable in whole or in part within 30 days following the first day of trading. The shares were listed and started trading on SIX Swiss Exchange on April 29, 2021 under the ticker symbol «PPGN».
Credit Suisse AG, Morgan Stanley Europe SE and Merrill Lynch International acted as Joint Global Coordinators and Joint Bookrunners, and Danske Bank A/S, Joh. Berenberg, Gossler &amp; Co. KG and Zürcher Kantonalbank as Joint Bookrunners on the IPO.
PolyPeptide is a leading global independent contract development and manufacturing organization (CDMO) specializing in innovative peptides employed as the active ingredient in therapeutic products. Dating back to 1952, PolyPeptide is the world’s first dedicated peptide manufacturer and at present manufactures approximately half of all currently approved peptide drug substances. For the year ended December 31, 2020, PolyPeptide generated revenues of EUR 223.0 m and an adjusted EBITDA of EUR 62.0 m. With a global workforce of more than 900 employees, PolyPeptide has manufacturing sites across three continents.
Homburger acted as counsel to the underwriters. The Homburger team was led by partner Frank Gerhard and included lead associate Lorenzo Togni and associate Daniel Junginger (all Corporate / M&amp;A and Capital Markets). Partner Stefan Oesterhelt provided tax advice.

Homburger advised the Underwriters on the IPO of PolyPeptide Group AG on SIX Swiss Exchange

Credit Suisse

Homburger acted as counsel to Credit Suisse (Switzerland) Ltd. and Investec Bank plc as mandated lead arrangers in connection with the financing of the acquisition of the majority of ASSEPRO Group by the European Private-Equity company EMZ Partners. ASSEPRO Group is a leading independent insurance broker company with a focus on small and medium-sized enterprises (SMEs) in Switzerland covering a broad value chain including brokerage, insurance advisory, risk management, pension schemes, financial/pension planning and employee benefits.
Homburger advised Credit Suisse (Switzerland) Ltd. and Investec Bank plc as mandated lead arrangers as well as the original lenders with regard to all legal aspects of the financing transaction.
The Homburger team was led by partner Jürg Frick (Financing and Investment Products) and included associates David Borer, Stefan Bindschedler and Daniel Junginger (all Financing and Investment Products) as well as partner Stefan Oesterhelt (Tax).

Homburger advised Credit Suisse (Switzerland) Ltd. and Investec Bank plc in connection with the financing of the acquisition of ASSEPRO Group by EMZ Partners

Daniel
Junginger

Homburger advises Santhera on the First Exchange Offer for a Convertible Bond in Switzerland and Issuance of New Senior Unsecured Convertible Bonds due 2024

Homburger advised the Underwriters on the IPO of PolyPeptide Group AG on SIX Swiss Exchange

Homburger advised Credit Suisse (Switzerland) Ltd. and Investec Bank plc in connection with the financing of the acquisition of ASSEPRO Group by EMZ Partners

Join the Team

Daniel Junginger

Career

Languages

Bar Registration

Teams

DanielJunginger

Homburger advises Santhera on the First Exchange Offer for a Convertible Bond in Switzerland and Issuance of New Senior Unsecured Convertible Bonds due 2024

Homburger advised the Underwriters on the IPO of PolyPeptide Group AG on SIX Swiss Exchange

Homburger advised Credit Suisse (Switzerland) Ltd. and Investec Bank plc in connection with the financing of the acquisition of ASSEPRO Group by EMZ Partners

Join the Team

Daniel Junginger

Career

Languages

Bar Registration

Teams

Daniel
Junginger